fig3

Figure 3. Performance of the iPAM classifier. Combination of patients from Mayo Clinic validation data (n = 235), Cleveland Clinic validation data (n = 182), and Thomas Jefferson University validation data (n = 139) were used to evaluate performance of the iPAM classifier. (A) Three risk groups [low- (iPAM risk score < 0.4), intermediate- (0.4 ≤ iPAM risk score ≤ 0.6), and high-risk (iPAM risk score > 0.6) group] showed highly significant differences in metastasis-free survival (P < 0.0001) from the Kaplan-Meier survival analysis. (B) Accuracy in predicting early metastasis (within five years of RP), quantified by AUC of ROC, was higher in young (≤ 55 years) (AUC = 0.87) and middle-aged patients (AUC = 0.82) than in old (> 70 years) patients (AUC = 0.69).